Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Aug 1, 2024
Deals
Platform, PKU asset drive Otsuka’s $800M takeout of Jnana
As lead program nears pivotal trial, Japanese pharma adds subsidiary to build U.S. discovery capabilities; deal gives strong exit to VC syndicate
BioCentury | Jun 23, 2020
Distillery Therapeutics
Blocking cGAS signaling for alcohol-related liver disease
BioCentury | Apr 12, 2018
Translation in Brief
Viral variant vaccine
How Singapore team rapidly designed live-attenuated Zika vaccine candidate
BioCentury | Aug 17, 2017
Translation in Brief
Stopping the invasion
How targeting the IRF3 pathway could prevent GBM recurrence
BioCentury | Jul 28, 2016
Targets & Mechanisms
Making sense of sensors
Targeting nucleic acid sensors makes sense for cancer
Items per page:
1 - 10 of 15